Cover Image


Oral Transmucosal Drug Delivery to 2018: Products, Players, Markets & Forecasts

出版商 Greystone Research Associates 商品编码 242925
出版日期 内容信息 英文
商品交期: 最快1-2个工作天内
Back to Top
口腔粘膜吸收型药物递输:产品、企业、市场及预测 Oral Transmucosal Drug Delivery to 2018: Products, Players, Markets & Forecasts
出版日期: 2014年05月01日 内容信息: 英文




  • 药物开发的演进
  • 市场、需求促进要素
  • 竞争情形


  • 口腔喷雾
  • 口腔薄膜、平板计算机
  • 舌下薄膜、晶圆



  • 吸收
  • 生物有效性
  • 附著力
  • 药物动力学


  • 肾上腺素抑制剂
  • 抗真菌药物
  • GABA受体激动剂
  • 荷尔蒙
  • 硝酸酯
  • Opioids(类鸦片物质)受体激动剂
  • Psychotropic Agents
  • 血清素 5-HT3 抑制剂



  • 药物中毒
  • 抗感染药
  • 心脏病
  • 糖尿病
  • 免疫疾病系
  • 感染疾病
  • 神经科
  • 肿瘤
  • 疼痛管理
  • 性的健康
  • 疫苗


  • 制剂、垄断平台
  • 政府法规专利
  • 从专利到期、Rx(处方药)转换到OTC(成药)



Product Code: TMC316K

In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism. On the provider side, the development of alternative methods of drug administration has improved the ability of physicians to manage specific problems. Practitioners now recognize the rapid onset, relative reliability, and the general lack of patient discomfort when drugs are administered by the transmucosal route. Growth in this sector will be driven by the pressure to extend market protection for numerous existing drugs with soon-to-expire patents.


  • Analyzes and evaluates oral transmucosal drug delivery technology platforms and their impact on the market
  • Analyzes oral transmucosal drug products and pipeline product candidates
  • Provides assessments of key oral transmucosal drug therapeutic categories
  • Provides market data and forecasts to 2018
  • Profiles market participants, their product development activities and strategies

What You Will Learn

  • What are the key segments and patient demographics that comprise the market for oral transmucosal drug delivery?
  • What are the major therapeutic demand drivers for transmucosal drug products?
  • What are the design factors and technologies that are being used in commercial and development-stage transmucosal products?
  • What is the market share and product position in the market and what will it look like in 2018?
  • Who are the companies behind the current generation of transmucosal drugs and what are their business models?
  • What is the role of pharma-device alliances and design partnerships in the commercialization and market access of new and emerging transmucosal products?
  • What is the impact of economic, technology, and regulatory factors?

Table of Contents

Executive Summary

Drug Delivery Market Dynamics

  • Evolution in Drug Development
  • Market and Demand Drivers
    • Shifting Patient Demographics
    • The Impact of Generics
    • Managed Care Initiatives
  • Competitive Landscape

Competing Transmucosal Delivery Technologies

  • Oral Sprays
  • Buccal Films and Tablets
  • Sublingual Films and Wafers

Commercial Transmucosal Formulation Platforms

Oral Transmucosal Drug Technology Factors

  • Absorption
  • Bioavailability
  • Adhesion
  • Pharmacokinetics

FDA-Approved Oral Transmucosal Products

  • Andrenergic Inhibitors
  • Antifungals
  • GABA Agonists
  • Hormones
  • Nitrates
  • Opioid Agonists
  • Psychotropic Agents
  • Serotonin 5-HT3 Inhibitors

Important Pipeline Product Candidates

Market Assessments & Forecasts

  • Addiction
  • Anti-infectives
  • Cardiology
  • Diabetes
  • Immunology
  • Infectious Disease
  • Neurology
  • Oncology
  • Pain Management
  • Sexual Health
  • Vaccines

Market Factors

  • Formulations and Proprietary Platforms
  • Government Regulations Patent
  • Expiration and Rx-to-OTC Switching

Market Participant Profiles

Back to Top